Christian Angermayer

Founder

Strategy and investor relations

• Serial entrepreneur and investor
• Co-founder, Ribopharma (RNAi translation, today Alnylam, $10bn market cap)
• Raised $1.5bn+ over the last 20 years for portfolio companies
• Invests across the entire lifecycle of a company and has been involved in more than 40 successful IPOs and M&As

Lars Wilde

Co-Founder

Advising on drug discovery and compound sourcing

• COO and Co-founder, COMPASS Pathways
• Former Co-founder and MD, Springlane
• Prior experience with Waterland Private Equity, global IVF clinics group, Boston Consulting Group
• Background: Finance and management

Florian Brand

Co-Founder and Chief Executive Officer

Executing drug development and operations

• Interim CEO, Perception Neuroscience
• Former Co-founder and MD, Springlane
• Prior experience with Rocket Internet, Allianz, Tanzanian German Program to Support Health
• Background: Economics and management

Simon Seibold

Associate

Investments and business development

• Founder of AI-based application with neural network approach
• Experience in venture capital with focus on digital health and therapeutics
• Background: Psychology, medicine and management

Philipp Schreiber

Associate

Drug discovery and compound sourcing

• Portfolio development, Apeiron Investment Group
• Experience in M&A transactions, venture capital and strategic management
• Background: Management, entrepreneurship and business law

ATAI is supporting the revival of treatments with prior evidence in humans, such as psilocybin and ketamine, in fighting mental health disorders

Depression, anxiety, post-traumatic stress disorder, obsessive-compulsive disorder, bipolar disorder and other psychiatric conditions are increasingly becoming a burden for patients, families and societies.

We believe that

• using psychedelic compounds in therapy could provide an opportunity to significantly advance psychiatry
• treatment solutions should be as convenient, cost-effective and fast as possible
• clinical evidence has to meet the highest scientific standards
• fully integrated mental health solutions are the future

ATAI is leveraging the potential of artificial intelligence (AI) and big data analytics to optimize and accelerate the drug development process

Technological innovation will enable us to consolidate and make sense of vast amounts of previously inaccessible data.

We believe that

• technology can be used to accelerate the identification and incubation of drug candidates and compounds
• AI and big data will improve clinical trial design, comparison and decision-making
• AI has a leading role in developing personalized therapeutics
• predictive analytics through unified machine learning models help us to predict the toxicity of drugs and the efficacy of combination therapeutics

Matthias Luz, MD

Chief Medical Officer

Developing clinical strategy for lead compounds

• 26+ years of experience in various leadership roles in the biopharmaceutical industry
• Broad experience in various disease areas (e.g. CNS and cardiovascular)
• Background: Board-certified anesthesiologist and researcher in Heidelberg and Harvard

Srinivas Rao, MD, PhD

Chief Scientific Officer

Advance the science into clinical evaluation

• 20+ years of experience in various CSO and CMO leadership roles
• Deep experience in IT
• Background: MS in computer engineering and MD and PhD in Neuropharmacology (Yale-trained)

Danny Talati

Lead, Business Development

Compound sourcing and evaluating

• 6+ years of neuroscience and neurology medical experience, Eli Lilly
• Prior experience in biotech business development and consulting
• Background: Pharmacy and management